Drugs that inhibit the sodium–glucose co-transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes. In populations that largely did not have heart failure at the time of enrolment, empagliflozin, canagliflozin and dapagliflozin decreased the risk of serious new-onset heart failure events by ≈30%. In addition, in the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of both pump failure and sudden deaths, the two most common modes of death among patients with heart failure. In none of the three trials could the benefits of SGLT2 inhibitors on heart failure be explained by the actions of these drugs as diuretics or anti-hyperglycaemic agents. These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality in patients with established heart failure, including those without diabetes. The EMPEROR-Reduced trial is enrolling ≈3600 patients with heart failure and a reduced left ventricular ejection fraction (≤ 40%), half of whom are expected not to have diabetes. Patients are being randomized to placebo or empagliflozin 10 mg daily, which is added to all appropriate treatment with inhibitors of the renin–angiotensin system and neprilysin, beta-blockers and mineralocorticoid receptor antagonists. The primary endpoint is the time-to-first event analysis of the combined risk of cardiovascular death and hospitalization for heart failure, but the trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death, all-cause mortality, and recurrent hospitalization events. By adjusting eligibility based on natriuretic peptide levels to the baseline ejection fraction, the trial will preferentially enrol high-risk patients. A large proportion of the participants is expected to have an ejection fraction < 30%, and the estimated annual event rate is expected to be at least 15%. The EMPEROR-Reduced trial is well-positioned to determine if the addition of empagliflozin can add meaningfully to current approaches that have established benefits in the treatment of chronic heart failure with left ventricular systolic dysfunction.

Packer, M., Butler, J., Filippatos, G., Jamal, W., Salsali, A., Schnee, J., et al. (2019). Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. EUROPEAN JOURNAL OF HEART FAILURE, 21(10), 1270-1278 [10.1002/ejhf.1536].

Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

Senni M.;
2019

Abstract

Drugs that inhibit the sodium–glucose co-transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes. In populations that largely did not have heart failure at the time of enrolment, empagliflozin, canagliflozin and dapagliflozin decreased the risk of serious new-onset heart failure events by ≈30%. In addition, in the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of both pump failure and sudden deaths, the two most common modes of death among patients with heart failure. In none of the three trials could the benefits of SGLT2 inhibitors on heart failure be explained by the actions of these drugs as diuretics or anti-hyperglycaemic agents. These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality in patients with established heart failure, including those without diabetes. The EMPEROR-Reduced trial is enrolling ≈3600 patients with heart failure and a reduced left ventricular ejection fraction (≤ 40%), half of whom are expected not to have diabetes. Patients are being randomized to placebo or empagliflozin 10 mg daily, which is added to all appropriate treatment with inhibitors of the renin–angiotensin system and neprilysin, beta-blockers and mineralocorticoid receptor antagonists. The primary endpoint is the time-to-first event analysis of the combined risk of cardiovascular death and hospitalization for heart failure, but the trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death, all-cause mortality, and recurrent hospitalization events. By adjusting eligibility based on natriuretic peptide levels to the baseline ejection fraction, the trial will preferentially enrol high-risk patients. A large proportion of the participants is expected to have an ejection fraction < 30%, and the estimated annual event rate is expected to be at least 15%. The EMPEROR-Reduced trial is well-positioned to determine if the addition of empagliflozin can add meaningfully to current approaches that have established benefits in the treatment of chronic heart failure with left ventricular systolic dysfunction.
Articolo in rivista - Articolo scientifico
Diabetes; Heart failure; Reduced ejection fraction; SGLT2 inhibitors; Trial design;
English
1270
1278
9
Packer, M., Butler, J., Filippatos, G., Jamal, W., Salsali, A., Schnee, J., et al. (2019). Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. EUROPEAN JOURNAL OF HEART FAILURE, 21(10), 1270-1278 [10.1002/ejhf.1536].
Packer, M; Butler, J; Filippatos, G; Jamal, W; Salsali, A; Schnee, J; Kimura, K; Zeller, C; George, J; Brueckmann, M; Anker, S; Zannad, F; Butler, J; Zannad, F; George, J; Brueckmann, M; Perrone, S; Nicholls, S; Janssens, S; Bocchi, E; Giannetti, N; Verma, S; Jian, Z; Spinar, J; Seronde, M; Bohm, M; Merkely, B; Chopra, V; Senni, M; Taddei, S; Tsutsui, H; Choi, D; Chuquiure, E; La Rocca, H; Ponikowski, P; Juanatey, J; Squire, I; Butler, J; Januzzi, J; Pina, I; Pocock, S; Carson, P; Doehner, W; Miller, A; Haas, M; Pehrson, S; Komajda, M; Anand, I; Teerlink, J; Rabinstein, A; Steiner, T; Kamel, H; Tsivgoulis, G; Lewis, J; Freston, J; Kaplowitz, N; Mann, J; Petrie, M; Bernstein, R; Cheung, A; Green, J; Januzzi, J; Kaul, S; Ping, C; Lip, G; Marx, N; Mccullough, P; Mehta, C; Rosenstock, J; Sattar, N; Scirica, B; Tsutsui, H; Wanner, C; Welty, F; Parhofer, K; Clayton, T; Pedersen, T; Lees, K; Konstam, M; Greenberg, B; Palmer, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/372815
Citazioni
  • Scopus 89
  • ???jsp.display-item.citation.isi??? 92
Social impact